Imagine Eyes’ rtx1™ Adaptive Optics Retinal Camera receives the CE mark
Orsay France and Milan Italy, September 7, 2012 – Imagine Eyes, the pioneer in cellular-level retinal imaging, is proud to announce that it has received regulatory approval to market its rtx1™ Adaptive Optics Retinal Camera* with the CE mark in the European Union.
“This is an important event as it marks the first time that an instrument specifically designed to image the retina at the cellular scale has received the CE mark for use by clinical ophthalmologists” explains Imagine Eyes CEO Nicolas Chateau. “The rtx1 can allow doctors in the EU to visualize their patients’ retinas with a level of detail heretofore unachievable in the clinic. They may be able to observe many of the cellular and microvascular structures that can be affected by the diseases that threaten the vision of millions of people every year.”
Imagine Eyes will be presenting the rtx1 on stand P333 during the ESCRS/Euretina joint meeting exhibition in Milan from September 7 through 11, 2012. For more information, please visit www.imagine-eyes.com or contact Mark Zacharria on +33 (0)1 64 86 15 66.
About Imagine Eyes – Imagine Eyes develops ophthalmic instruments that analyze the eye at the microscopic scale. Conceived from a revolutionary technology, adaptive optics, its products enable cellular-level retinal imaging, precision measurement of the eyes’ refractive errors and vision simulation. Founded in 2003 in Orsay, France by photonics and ophthalmic industry specialists, the company is ISO 9001 and 13485 certified. It maintains its position as a technology leader thanks to its intensive R&D program, broad portfolio of patents and the marketing of cutting-edge products that have been rapidly adopted by its customers.
* Important notice – The rtx1 is available outside of the European Union for use as a Research Use Only device where such use is authorized by local governing regulations.
- Contact Information
- Mark Zacharria
- Director of Global Communications
- Imagine Eyes
- (33) 681559906
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.